Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis
Obesity Science & Practice · 2024-12 · 10 (6)
DOI: 10.1002/osp4.70032 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity Science & Practice, online erschienen am 24.12.2024. Verfasst von A B M Kamrul-Hasan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology Mymensingh Medical College Mymensingh Bangladesh. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Endogenous glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) regulate islet cell function. GLP‐1 receptor agonists (GLP‐1RAs) have been associated with an elevated risk of acute pancreatitis. Data on the pancreatic safety of tirzepatide (a dual GLP‐1 and GIP agonist) and its effects on islet cell function in randomized controlled trials (RCTs) are scarce. Moreover, no meta‐analysis has comprehensively examined such effects of tirzepatide.
Methods
Electronic databases were searched for RCTs with tirzepatide as the intervention and a placebo or active comparator as the control. The primary outcome was adjudication‐confirmed pancreatitis; secondary outcomes were the percent changes from baseline in serum pancreatic amylase, lipase, insulin, C‐peptide, glucagon, and homeostasis model assessment of insulin resistance (HOMA2‐IR).
Results
Seventeen RCTs with 18 published reports involving 14,645 subjects were analyzed. Over a follow‐up duration of 12–72 weeks, tirzepatide had identical risks of pancreatitis to placebo (tirzepatide 5 mg: RR 2.04, 95% CI [0.27–15.69], p = 0.49; 10 mg: RR 0.63, 95% CI [0.08–5.12], p = 0.67; and 15 mg: RR 1.26, 95% CI [0.36–4.98], p = 0.72). Tirzepatide was also associated with comparable risks of pancreatitis to insulin and GLP‐1RAs. However, tirzepatide (at all doses) caused greater increases in pancreatic amylase and lipase than placebo and insulin. Individuals on tirzepatide 15 mg and GLP‐1RAs had similar risks of having increased lipase levels. The percent reductions in fasting insulin were greater with tirzepatide 10 and 15 mg than with placebo. All doses of tirzepatide caused greater percent reductions in fasting insulin, C‐peptide, and glucagon than GLP‐1RAs. Compared to placebo and GLP‐1RAs, the percent reductions in HOMA2‐IR were greater with all doses of tirzepatide.
Conclusion
The meta‐analysis provides evidence of the safety of tirzepatide regarding pancreatitis and establishes its positive effect on islet cell functions and insulin resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology Mymensingh Medical College Mymensingh Bangladesh.
- Department of Endocrinology NRS Medical College Kolkata India.
- Department of Endocrinology CEDAR Superspeciality Clinics New Delhi India.
- Department of Endocrinology JSS Medical College JSS Academy of Higher Education & Research Mysore India.
- Department of Medicine Sylhet MAG Osmani Medical College Sylhet Bangladesh.
- Department of Endocrinology and Metabolism Lancashire Teaching Hospitals NHS Trust & Manchester Metropolitan University Preston UK.
ORCID-Profile: A B M Kamrul-Hasan, Sunetra Mondal, Deep Dutta, Lakshmi Nagendra, Mohammed Ruhul Kabir, Joseph M Pappachan
Zitieren
APA
Kamrul-Hasan, A. B. M., Mondal, S., Dutta, D., Nagendra, L., Kabir, M. R., & Pappachan, J. M. (2024). Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis. Obesity Science & Practice, 10(6). https://doi.org/10.1002/osp4.70032
Vancouver
Kamrul-Hasan ABM, Mondal S, Dutta D, Nagendra L, Kabir MR, Pappachan JM. Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis. Obesity Science & Practice. 2024;10(6). doi:10.1002/osp4.70032
BibTeX
@article{KamrulHasan2024,
author = {Kamrul-Hasan, A B M and Mondal, Sunetra and Dutta, Deep and Nagendra, Lakshmi and Kabir, Mohammed Ruhul and Pappachan, Joseph M},
title = {Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis},
journal = {Obesity Science & Practice},
year = {2024},
volume = {10},
number = {6},
doi = {10.1002/osp4.70032}
}
EUVIMED